[Has low-dosage therapy with the oral contraceptive Ovosiston any effect on glucose tolerance and liver function?].
D000410:Alanine Transaminase / Q000097:blood; D000429:Alcohol Oxidoreductases / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D050260:Carbohydrate Metabolism; D002715:Chlormadinone Acetate / Q000008:administration & dosage; D003276:Contraceptives, Oral / Q000008:administration & dosage*; D005260:Female; D005632:Fructose; D005634:Fructose-Bisphosphate Aldolase / Q000097:blood; D005951:Glucose Tolerance Test; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D007931:Leucyl Aminopeptidase / Q000097:blood; D008111:Liver Function Tests; D008656:Mestranol / Q000008:administration & dosage; D013012:Sorbitol
D003276:Contraceptives, Oral; D002715:Chlormadinone Acetate; D005632:Fructose; D013012:Sorbitol; D008656:Mestranol; D000429:Alcohol Oxidoreductases; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D007931:Leucyl Aminopeptidase; D005634:Fructose-Bisphosphate Aldolase
Hat die Behandlung mit dem oralen Kontrazeptivum Ovosiston in niedriger Dosierung einen Einfluss auf Glukosetoleranz und Leberfunktion.